Viral infection in hematopoietic stem cell transplantation: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review on the role of cellular therapy in prevention and treatment |
| |
| Affiliation: | 1. Department of Pediatrics, MedStar Georgetown University Hospital, Washington, District of Columbia, USA;2. Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, California, USA;3. Pediatric Blood and Marrow Transplantation Division and Pele Pequeno Principe Research Institute, Hospital Pequeno Principe, Curitiba, Brazil;4. Gastroenterology Unit, Department of Medicine, A.O.U.I. Policlinico G.B. Rossi & University of Verona, Verona, Italy;5. Université de Montréal and Maisonneuve Rosemont Hospital, Montréal, Québec, Canada;6. Department of Haematology, Fiona Stanley Hospital, Perth, Western Australia, Australia;7. IRCCS Ospedale San Raffaele, Segrate, Milan, Italy;8. Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania, USA;9. Department of Bone Marrow Transplantation and Cellular Therapy, St Jude Children''s Research Hospital, Memphis, Tennessee, USA;10. Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK;11. Stem Cell Transplantation and Cellular Therapies, Memorial Sloan Kettering Cancer Center, and Department of Pediatrics, Weill Cornell Medical College of Cornell University, New York, New York, USA;12. Dana-Farber/Boston Children''s Cancer and Blood Disorders Center, Boston, Massachusetts USA;13. Center for Cancer and Immunology Research, CETI, Children''s National Hospital, Washington, District of Columbia, USA;1. denovoMATRIX GmbH, Dresden, Germany;2. Universitätskrankenhaus Carl Gustav Carus der Technischen Universität Dresden, Dresden, Germany;3. CELLnTEC Advanced Cell Systems AG, Bern, Switzerland;1. Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland;2. Department of Radiation Oncology, Stanford University, Stanford, California;3. Departments of Radiology, Radiation Oncology and Biomedical Engineering, University of Iowa, Iowa City, Iowa;1. Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada;2. Centre for Journalology, Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Canada;3. School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Canada;4. Department of Anesthesiology and Pain Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada;5. Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada;6. Neonatology, Department of Pediatrics, Children''s Hospital of Eastern Ontario (CHEO) and CHEO Research Institute, Ottawa, ON, Canada;1. Division of Cardiology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania;2. Division of Cardiology, Department of Medicine, Brigham and Women''s Hospital, Boston, Massachusetts;3. Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland;4. Human Genetics Center, Department of Epidemiology, Human Genetics, and Environmental Sciences, The University of Texas Health Science Center at Houston, Houston, Texas;5. Baylor College of Medicine, Human Genome Sequencing Center, Houston, Texas;6. Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi;1. Cardiovascular Division;2. Department of Medicine, Brigham and Women''s Hospital, Boston, Massachusetts;3. Division of Cardiovascular Medicine, Stanford University, Palo Alto, California;4. Montreal Heart Institute Department of Medicine and Research Centre, and Université de Montréal, Montréal, Québec, Canada;5. Division of Cardiology, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil;6. Estudios Cardiológicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina;7. Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland;8. Division of Cardiology, University of Michigan, Ann Arbor, Michigan;2. Division of Cardiac Anesthesiology, Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital-Harvard Medical School, Boston, MA;3. Department of Anesthesiology, Perioperative Care & Pain Medicine, NYU Grossman School of Medicine, New York City, NY;4. Department of Anesthesiology, The Ohio State University Wexner Medical Center, Columbus, OH;5. Professor, Clinical, Department of Anesthesiology, University of California, San Diego, UCSD Medical Center, San Diego, CA |
| |
| Abstract: | Despite recent advances in the field of HSCT, viral infections remain a frequent causeof morbidity and mortality among HSCT recipients. Adoptive transfer of viral specific T cells has been successfully used both as prophylaxis and treatment of viral infections in immunocompromised HSCT recipients. Increasingly, precise risk stratification of HSCT recipients with infectious complications should incorporate not only pretransplant clinical criteria, but milestones of immune reconstitution as well. These factors can better identify those at highest risk of morbidity and mortality and identify a population of HSCT recipients in whom adoptive therapy with viral specific T cells should be considered for either prophylaxis or second line treatment early after inadequate response to first line antiviral therapy. Broadening these approaches to improve outcomes for transplant recipients in countries with limited resources is a major challenge. While the principles of risk stratification can be applied, early detection of viral reactivation as well as treatment is challenging in regions where commercial PCR assays and antiviral agents are not readily available. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
